尿道下裂应探索多远?对大型尿道下裂患者队列应用二代测序
该前瞻性多中心研究纳入293例尿道下裂患儿,在排除AR致病变异后对284例进行336基因NGS检测,发现5.5%的患者存在可能致病变异,且检出率随尿道下裂严重程度增加;NGS可揭示轻度性发育异常、未诊断综合征及新候选基因变异,提示即使轻度尿道下裂患者也能从测序中获益。
要点
- NGS在尿道下裂患儿中检出可能致病变异率为5.5%。
- 检出率随尿道下裂严重程度增加而升高。
- NGS可发现轻度DSD、未诊断综合征及新候选基因变异。
核心结论
- NGS可揭示轻度性发育异常、未诊断综合征或新基因的候选罕见变异,提示即使轻度尿道下裂患者也能从先进测序技术中获益。
- 早期分子诊断有助于改善青春期随访及对最初未诊断综合征的医疗咨询。
研究设计与样本
- 前瞻性多中心研究纳入293例阴茎头型至阴茎阴囊型尿道下裂患儿(无隐睾及小阴茎)。
- 经Sanger测序排除可能致病性AR变异后,对284例患者使用包含336个基因的NGS panel检测。
主要发现
- 综合考虑Sanger测序和NGS,16例(5.5%)患者检出可能致病变异。
- 涉及DSD相关基因(AR、NR5A1、HSD17B3和MAMLD1),反向表型分析发现MID1相关中线缺陷综合征和RARA相关维甲酸信号通路异常。
- 覆盖度分析发现18q缺失。
- 检出可能致病变异随尿道下裂严重程度增加而增加。
- 还发现涉及低促性腺激素性性腺功能减退、Noonan综合征和生殖结节发育基因的VUS。
关键数值与推荐
- 使用REVEL、ClinVar及内部工具(Captain-ACHAB、MobiCNV和MobiDetails)评估致病变异和可能致病变异。
临床怎么用
- NGS不应仅限于性发育异常病例,即使轻度尿道下裂患者也应考虑早期基因检测以发现遗传缺陷或综合征。
- 早期分子诊断有助于改善青春期随访和医疗咨询。
局限性
- 遗传研究主要关注外显子变异,大多数病例仍无法解释。
- VUS的贡献有待未来研究改进诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Next-generation sequencing (NGS) is generally used for patients with severe disorders of sex development (DSD). However, NGS has not been applied extensively for patients with hypospadias only, and most affected children do not benefit from an etiological diagnosis. OBJECTIVE: To evaluate the clinical usefulness of NGS for patients with hypospadias, regardless of severity. DESIGN, SETTING, AND PARTICIPANTS: Prospective multicenter research included 293 children with glandular to penoscrotal hypospadias (no undescended testis and no micropenis). After excluding likely pathogenic androgen receptor (AR) variants by Sanger sequencing, an NGS panel tested 336 genes including unexplored candidates in 284 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The rate of pathogenic and likely pathogenic variants was assessed using REVEL, ClinVar, and in-house tools (Captain-ACHAB, MobiCNV, and MobiDetails). RESULTS AND LIMITATIONS: Likely pathogenic variants were identified in 16 (5.5%) patients with both Sanger sequencing and NGS taken into account. Some genes were related to DSD (AR, NR5A1, HSD17B3, and MAMLD1), but reverse phenotyping revealed two syndromic disorders with midline defects (MID1) and alteration in the retinoic acid signaling pathway (RARA). Coverage analysis revealed an 18q deletion. Identification of likely pathogenic variants increased with hypospadias severity. Other variants of unknown significance (VUSs) in genes implicated in hypogonadotropic hypogonadism, Noonan syndrome, and genital tubercle development were also identified. Genetic study mainly focused on exonic variants, and most cases remain unexplained. CONCLUSIONS: NGS reveals minor forms of DSD, undiagnosed syndromes, or candidate rare variants in new genes, indicating that even patients with mild hypospadias benefit from advanced sequencing techniques. Early molecular diagnosis would help improve follow-up at puberty and medical counseling for initially undiagnosed syndromes. Future studies will improve the diagnosis by investigating the contribution of VUSs. PATIENT SUMMARY: Next-generation sequencing enables simultaneous testing of numerous genes and should not be limited to disorders of sex development cases. Even patients with mild hypospadias would benefit from early diagnosis of a genetic defect implicated in sex development or other syndromes.
引用
- Ea V, Bergougnoux A, Philibert P, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur Urol. 2021. PMID: 33468338. doi:10.1016/j.eururo.2020.12.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。